Hepatic Encephalopathy Global Market Report 2024

The global hepatic encephalopathy market has grown strongly in recent years. It will grow from $1.62 billion in 2023 to $1.72 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.

The global hepatic encephalopathy market is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.

The hepatic encephalopathy market is expected to experience growth due to the increasing prevalence of liver diseases. Liver diseases encompass medical conditions that affect the liver and impair its function. Treatments for liver diseases, such as hepatic encephalopathy, can alleviate symptoms, slow down disease progression, enhance liver function, and reduce the occurrence of hepatic encephalopathy by effectively managing underlying conditions. This can potentially result in a reduced frequency and severity of hepatic encephalopathy episodes, ultimately improving the overall quality of life for patients. For example, in March 2023, the Office For Health Improvement And Disparities, a UK-based government organization, reported a 3.7% increase in premature deaths from liver disease in 2021, with the number rising from 10,501 in 2020 to 10,127. Consequently, the growing prevalence of liver diseases is a key driver of the hepatic encephalopathy market.

The hepatic encephalopathy market is expected to experience growth due to rising healthcare expenditures. Healthcare expenditures encompass the total resources allocated to healthcare-related services, products, and activities within a specific timeframe, whether on an individual, community, national, or global scale. Increased healthcare spending can have a positive impact on hepatic encephalopathy treatment options, enabling advancements in diagnosis, treatment, awareness, and patient care. For example, in May 2023, the Office for National Statistics reported a 9.4% increase in healthcare spending in the UK in nominal terms and a 9.7% increase in real terms. Total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion) in 2021, with pharmaceutical spending at $51.84 billion (£39.6 billion) for the same year. Moreover, preventive care spending reached $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the growth of the hepatic encephalopathy market will be driven by the increasing healthcare expenditure.

The growth of the hepatic encephalopathy market in the forecast period may face constraints due to the high cost of treatment, which can impede access to care. The elevated expenses associated with treatment can create barriers for patients dealing with hepatic encephalopathy, particularly for those lacking sufficient insurance coverage. This situation can lead to delayed diagnosis and treatment, potentially worsening the condition and increasing the risk of complications. For example, a report published by the Australian Institute of Health and Welfare in November 2022 revealed a 7.1% increase in total health spending (both recurrent and capital) in 2019-20. While this growth rate exceeded the average annual rate during the preceding decade leading up to 2020-21 (3.4%), it primarily indicated a return to pre-pandemic health spending patterns, particularly in non-government spending. Consequently, the high cost of treatment remains a hindrance to the hepatic encephalopathy market's growth.

Prominent companies operating in the hepatic encephalopathy market are actively involved in the development of innovative drugs aimed at treating hepatic encephalopathy. These efforts are driven by the desire to gain a competitive edge and reinforce their market position. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, introduced the novel GR3027 (golexanolone) for the treatment of hepatic encephalopathy. GR3027 is an orally administered small molecule classified as a GABAA-receptor-modulating steroid antagonist (GAMSA), designed to counteract positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is undergoing clinical trials for the treatment of hepatic encephalopathy, specifically for chronic hepatic encephalopathy (CHE) in Phases I/IIa.

In September 2022, Genfit SA., a France-based biotechnology company, completed the acquisition of Versantis AG for an undisclosed sum. Through this strategic move, Genfit aims to expand its product pipeline to address other liver diseases characterized by unmet medical needs. Versantis, headquartered in Switzerland, is a biotechnology company specializing in the development of drugs for hepatic encephalopathy.

Major players in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.

North America was the largest region in the hepatic encephalopathy market in 2023. The regions covered in hepatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The main drug types of hepatic encephalopathy are antibiotics, laxatives, l-ornithine, l-aspartate and others. Antibiotics are a class of medications that are used to treat bacterial infections and helps lower the overall ammonia load in the body, which can contribute to the neurological symptoms associated with hepatic encephalopathy. The various route of administration including oral, intravenous and rectal which are distributed through various distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies.

This report provides hepatic encephalopathy market statistics, including hepatic encephalopathy industry global market size, regional shares, competitors with a hepatic encephalopathy market share, detailed hepatic encephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the hepatic encephalopathy industry. This hepatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.